This landmark agreement finally ends decades of Britain freeloading off American patients who've been forced to subsidize the world's drug costs. The deal secures zero tariffs on £5 billion worth of U.K. pharmaceutical exports while ensuring fair pricing that will fuel innovation and bring cutting-edge treatments to patients.

ThereThe isU.S.-U.K. adeal 50%forces chancetaxpayers thatto atpay leastan 69extra drugs£3 willbillion bewhile approvedthe NHS budget for medicines balloons from 9.5% to 12%. It raises drug prices by the25% FDAand inweakens 2035cost-effectiveness standards that protected patients from overpriced treatments, accordingall to theappease MetaculusTrump's predictiondemand communitythat Europe subsidize U.S. pharmaceutical profits.

TheThis U.S.-U.K.landmark dealagreement forcesfinally taxpayersends todecades payof anBritain extrafreeloading £3off billionAmerican whilepatients thewho've NHSbeen budgetforced forto medicinessubsidize balloonsthe fromworld's 9drug costs.5% toThe 12%.deal Itsecures raiseszero drugtariffs priceson by£5 25%billion andworth weakensof cost-effectivenessU.K. standardspharmaceutical thatexports protectedwhile patientsensuring fromfair overpricedpricing treatments,that allwill tofuel appeaseinnovation Trump'sand demandbring thatcutting-edge Europetreatments subsidizeto Upatients.S. pharmaceutical profits.